Table 3.
Treatment Response by HNL Stage and HNC Treatment
| n=733 | Improved | Odds ratio (unadjusted) | Odds ratio (adjusted)* | p-value | |
|---|---|---|---|---|---|
| Lymphedema program | |||||
| Home | 647 | 377 (58%) | 1.0 (reference) | 1.0 (reference) | |
| Outpatient | 86 | 62 (72%) | 1.9 (1.1-3.1) | 1.3 (0.7-2.1) | 0.383 |
| Self-reported adherence | |||||
| None | 91 | 29 (32%) | 1.0 (reference) | 1.0 (reference) | |
| Partial | 372 | 209 (56%) | 2.7 (1.7-4.5) | 3.3 (2.0-5.6) | |
| Full | 270 | 201 (74%) | 6.2 (3.7-10.4) | 8.1 (4.6-14.4) | <0.001 |
| HNL Stage | |||||
| 0 | 2 | 1 (50%) | 1.0 (reference) | ||
| 1a | 178 | 96 (54%) | 1.2 (0.1-19.0) | ||
| 1b | 487 | 294 (60%) | 1.5 (0.1-24.5) | ||
| 2 | 66 | 48 (73%) | 2.7 (0.2-44.9) | ||
| HNC treatment | |||||
| XRT | 218 | 115 (53%) | 1.0 (reference) | 1.0 (reference) | |
| Surgery | 91 | 65 (71%) | 2.2 (1.3-3.8) | 2.3 (1.3-4.0) | 0.004 |
| Surgery and XRT | 424 | 259 (61%) | 1.4 (1.0-2.0) | 1.3 (0.9-1.8) | 0.196 |
| Tumor site | |||||
| Larynx/hypopharynx | 160 | 92 (58%) | 1.0 (reference) | ||
| Oral cavity | 167 | 98 (59%) | 1.0 (0.7-1.6) | ||
| Oropharynx/nasopharynx | 242 | 146 (60%) | 1.1 (0.7-1.7) | ||
| Other | 164 | 103 (63%) | 1.3 (0.8-2.0) | ||
| Latency to HNL referral | |||||
| <6 weeks | 197 | 113 (57%) | 1.0 (reference) | ||
| 6 weeks to 2 months | 217 | 136 (63%) | 1.2 (0.8-1.9) | ||
| 3 to 5 months | 202 | 124 (61%) | 1.2 (0.8-1.8) | ||
| 6+ months | 17 | 66 (56%) | 1.0 (0.6-1.5) | 0.001 |
*
final multivariate logistic regression model assessing independent effect of lymphedema program and adherence retained the following adjustment variables: HNC treatment group and duration follow-up.
p-values from multivariate model shown